Boehringer Ingelheim and Simcere Pharmaceutical Group have signed a licence and collaboration agreement to develop SIM0709, a pre-clinical TL1A/IL-23p19 bispecific antibody, for the treatment of inflammatory bowel disease (IBD). The partnership aims to advance the candidate through global development. SIM0709
MS Pharma Group has entered into a strategic partnership with Hetero Group to localize five established biosimilars across oncology, immunology, and hematology in Algeria. The agreement aims to expand access to biologic medicines through a localization and technology transfer approach.
Genentech, a member of the Roche Group, has expanded its investment in a new manufacturing facility in Holly Springs, North Carolina, increasing the total commitment to around $2 billion. The move builds on an initial investment announced in May 2025
Novo Nordisk received FDA approval Monday (22nd December) for oral Wegovy (semaglutide), marking the first oral GLP-1 receptor agonist cleared for obesity treatment. The Danish drugmaker plans a full US launch in early January 2026, with manufacturing underway at its
AstraZeneca announced plans to invest $2 billion to expand its long-standing manufacturing footprint in Maryland, including a significant expansion of its flagship biologics facility in Frederick and construction of a new state-of-the-art facility in Gaithersburg for clinical supply of molecules
On November 21st 2025 Eli Lilly became the first pharmaceutical company to reach a $1 trillion market valuation this week, worth more than twice the value of any other drugmaker. The company’s stock has soared on the back of the
Novartis has announced plans to expand its operations in North Carolina with the creation of a new flagship manufacturing hub. The investment forms part of the company’s five-year, $23 billion commitment to build end-to-end manufacturing capacity for its key medicines
Novartis has announced the opening of a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California. The new site is part of the company’s previously announced $23 billion investment in US infrastructure over the next five years. The facility,
Novo Nordisk and Pfizer have escalated their competing bids for obesity drug developer Metsera to approximately $10 billion, transforming what began as a straightforward acquisition into a high-stakes corporate battle marked by legal challenges and regulatory scrutiny. Metsera’s board declared
Eli Lilly and Company has announced plans to construct a new $3 billion manufacturing facility in Katwijk, the Netherlands, located within the Leiden Bio Science Park. The facility will expand Lilly’s global capacity to produce oral medicines and strengthen its
